Loss of endogenous mouse mammary tumor virus superantigen increases tumor resistance

Journal of Immunology

Volumn 161, Issue 2, 1998, Pages 563-570

  Schirrmacher, Volker ^a   Beutner, Ulrich ^a,b   Bucur, Marianna ^a   Umansky, Victor ^a   Rocha, Marian ^a   Von Hoegen, Paul ^a,c  

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^b UNIVERSITY HOSPITAL WÜRZBURG   (Germany)

^c GLAXOSMITHKLINE BIOLOGICALS   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

DNA; SUPERANTIGEN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; ENVELOPE GENE; GRAFT VERSUS HOST REACTION; GRAFT VERSUS LEUKEMIA EFFECT; INBRED STRAIN; LONG TERMINAL REPEAT; MOUSE; MOUSE MAMMARY TUMOR ONCOVIRUS; MOUSE STRAIN; NONHUMAN; PRIORITY JOURNAL; SURVIVAL; T CELL LYMPHOMA; TUMOR RESISTANCE;

ANIMALS; ANTIGENS, VIRAL; CROSSES, GENETIC; DISEASE SUSCEPTIBILITY; DNA, VIRAL; GRAFT VS HOST REACTION; IMMUNITY, NATURAL; LYMPHOMA, T-CELL; MAMMARY TUMOR VIRUS, MOUSE; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; MICE, INBRED CBA; MICE, INBRED DBA; PROVIRUSES; RETROVIRIDAE INFECTIONS; SUPERANTIGENS; TUMOR CELLS, CULTURED; TUMOR VIRUS INFECTIONS;

EID: 0032528346     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (40)

1. Schirrmacher, V. 1981. Immunogenetic studies on the resistance of mice to highly metastatic DBA/2 tumor cell variants. I. Effect of incompatibilties at H-2 or non-H-2 genes in normal and nude (nu/nu) mice. Invasion Metastasis 1:4.
2. Schirrmacher, V., S. Landolof, R. Zawatzky, and H. Kirchner. 1981. Immunogenetic studies on the resistance of mice to highly metastatic DBA/2 tumor cell variants. II. Influence of minor histocompatibility antigens on tumor resistance, γ interferon induction and cytotoxic response. Invasion Metastasis 1:175.
3. Davey, G. C., G. A. Carrie, and P. Alexander. 1976. Spontaneous shedding and antibody induced modulation of histocompatibility antigens on murine lymphomata: correlation with metastatic spread. Br. J. Cancer 33:9.
4. Bosslet, K., and V. Schirrmacher. 1981. Escape of metastasizing clonal tumor cell variants from tumor-specific cytolytic T lymphocytes. J. Exp. Med. 154:557.
5. Bosslet, K., and V. Schirrmacher. 1982. High-frequency generation of new immunoresistant tumor variants during metastasis of a cloned murine tumor line (ESb). Int. J. Cancer 29:195.
6. Schirrmacher, V., and U. Zangemeister-Wittke. 1994. γ-Irradiation suppresses T-cell mediated protective immunity against a metastatic tumor in the afferent phase of the immune response but enhances it in the efferent phase if given before immune cell transfer. Int. J. Oncol. 4:335.
7. Bosslet, K., V. Schirrmacher, and G. Shantz. 1979. Tumor metastases and cell-mediated immunity in a model system in DBA/2 mice. VI. Similar specificity patterns of protective anti-tumor immunity in vivo and of cytolytic T cells in vitro. Int. J. Cancer 24:303.
8. Von Hoegen, P., P. Altevogt, and V. Schirrmacher. 1987. New antigens presented on tumor cells can cause immune rejection without influencing the frequency of tumor-specific cytolytic T cells. Cell. Immunol. 109:338.
9. Schirrmacher, V., A. Griesbach, M. Gehring, and B. Lehr. 1996. Genetic separation of GvL and GvH reactivity in new recombinant-inbred tumor-resistant mouse strains. Int. J. Oncol. 8:1035.
10. Schirrmacher, V., P. von Hoegen, A. Griesbach, and U. Zangemeister-Wittke. 1991. Specific eradication of micrometastases by transfer of tumor immune T-cells from MHC congenic mice. Cancer Immunol. Immunother. 32:373.
11. Zangemeister-Wittke, U., and V. Schirrmacher. 1991. Transfer of long-lasting tumor immunity by immune T cells from MHC congenic mice: migration, survival and tumor protectivity of cytotoxic donor cells. Biotherapy 3:319.
12. Acha-Orbea, H., and H. R. MacDonald. 1995. Superantigens of mouse mammary tumor virus. Annu. Rev. Immunol. 13:459.
13. Janeway, C. A. J. 1991. Selective elements for the vβ region of the T-cell receptor: Mls and the bacterial toxin mitogens. Adv. Immunol. 50:1.
14. a. Cell 61:1365.
15. Landolfo, S., F. Marcucci, V. Schirrmacher, and H. Kirchner. 1981. Characteristics of alloantigen and cellular mechanisms responsible for γ-interferon production in primary murine MLC. J. Interferon Res. 1:339.
16. a induces interferon-γ but fails to trigger cytotoxicity. Eur. J. Immunol. 22:2789.
17. Woodland, D., M. P. Happ, J. Bill, and E Palmer. 1990. Requirement for cotolerogenic gene products in the clonal deletion of I-E reactive T cells. Science 247:964.
18. Marrack, P., E. Kushnir, and J. Kappler. 1991. A maternally inherited superantigen encoded by a mammary tumor virus. Nature 349:524.
19. Frankel, W. N., C. Rudy, J. M. Coffin, and B. T. Huber 1991. Linkage of Mls genes to endogenous mammary tumor viruses of inbred mice. Nature 349:526.
20. a antigens in vivo. Immunol. Rev. 131:169.
21. Luther, S. A., and H. Acha-Orbea. 1997. Mouse mammary tumor virus: immunological interplays between virus and host. Adv. Immunol. 65:139.
22. Schirrmacher, V., G. Shantz, G. Clauer, D. Komitowski, H. P. Zimmermann, and M. L. Lohmann-Matthes. 1979. Tumor metastases and cell-mediated immunity in a model system in DBA/2 mice. I. Tumor invasiveness in vitro and metastases formation in vivo. Int. J. Cancer 23:233.
23. Schirrmacher, V., H.-J. Schild, B. Gückel, and P. von Hoegen. 1992. Tumor specific CTL response requiring interactions of four different types and dual recognition of MHC class I and class II restricted tumor antigens. Immunol. Cell Biol. 71:311.
24. Ausubel, F. M., R. Brent, E. Kingston, D. D. Moore, J. G. Seidman, J. A. Smith, and K. Struhl. 1987. Current Protocols in Molecular Biology. John Wiley and Sons, New York.
25. Beutner, U., W. N. Frankel, M. S. Cote, J. M. Coffin, and B. T. Huber. 1992. Mls-1 is encoded by the long terminal repeat open reading frame of the mouse mammary tumor provirus Mtv-7. Proc. Natl. Acad. Sci. USA 89:5432.
26. Majors, J. E., and H. E. Varmus. 1983. Nucleotide sequencing of an apparent proviral copy of env mRNA defines determinants of expression of the mouse mammary tumor virus env gene. J. Virol. 47:495.
27. Kozak, C., G. Peters, R. Pauley, V. Morris, R. Michalides, J. Dudley, M. Green, M. Davisson, O. Prakash, and A. Vaidya. 1987. A standardized nomenclature for endogenous mouse mammary tumor viruses. J. Virol. 61:1651.
28. Lee, B. K., and E. M. Eicher. 1990. Segregation patterns of endogenous mouse mammary tumor viruses in five recombinant inbred strain sets. J. Virol. 64:4568.
29. Scherer, M. T., L. Ignatowicz, G. M. Winslow, J. W. Kappler, and P. Marrack. 1993. Superantigens: bacterial and viral proteins that manipulate the immune system. Annu. Rev. Cell Biol. 9:101.
30. MacDonald, H. R., R. Schneider, R. K. Lees, R. C. Howe, H. Acha-Orbea, H. Festenstein, R. Zinkernagel, and H. Hengartner. 1988. T-cell receptor vβ use predicts reactivity and tolerance to Mls-encoded antigens. Nature 332:40.
31. Morris, V. L., E. Medeiros, G. M. Ringold, J. M. Bishop, and H. E. Varmus. 1977. Comparison of mouse mammary tumor virus-specific DNA in inbred, wild and Asian mice, and in tumors and normal organs from inbred mice. J. Mol. Biol. 114:73.
32. Lukacher, A. E., Y. Ma, J. P. Carroll, S. R. Abromson-Leeman, J. C. Laning, M. E. Dorf and T. L. Benjamin. 1995. Susceptibility to tumors induced by polyoma virus is conferred by an endogenous mouse mammary tumor virus superantigen. J. Exp. Med. 181:1683.
33. + T cells. J. Immunol. 150:5519.
34. Schirrmacher, V., P. Beckhove, A. Krüger, M. Rocha, V. Umansky. K.-P. Fichtner, W. E. Hull, U. Zangemeister-Wittke, A. Griesbach, K. Jurianz, and P. von Hoegen. 1995. Effective immune rejection of advanced metastasized cancer. Int. J. Oncol. 6:505.
35. Schirrmacher, V. 1979. Tumor metastases and cell-mediated immunity in a model-system in DBA/2 mice. V. Transfer of protective immunity with H-2 identical immune T cells from B10.D2 mice. Int. J. Cancer 24:80.
36. 1H-NMR microimaging with respiratory triggering for monitoring adoptive immunotherapy of metastatic mouse lymphoma. Magnetic Resonance Med. 38:440.
37. 31P-NMR spectroscopy, in vivo monitoring of the local antitumor effects of systemic immune cell transfer. Int. J. Cancer 66:484.
38. Rocha, M., V. Umansky, K. Lee, H.-J. Hacker, A. Benner, and V. Schirrmacher. 1997. Differences between graft-versus-leukemia (GvL) and graft-versus-host (GvH) reactivity. I. Interaction of donor immune T cells with tumor and/or host cells. Blood 6:2189.
39. Thomson, B. J., and J. Nicholas. 1991. Superantigen function. Nature 351:530.
40. Sutkowski, N., T. Palkama, C. Ciurli, R. P. Sekely, D. A. Thorley-Lawson, and B. T. Huber. 1996. An Epstein-Barr virus-associated antigen. J. Exp. Med. 184:971.